Our Pricing

Mounjaro £20 discount Code UK: How to Save on Weight Loss Treatment

Published on: June 03, 2026

Searching for a genuine mounjaro £20 discount code uk offer? Cured Pharmacy provides transparent pricing on Mounjaro weight loss injections from £124.99 with an exclusive £20 discount using code WEIGHTLOSSNEW at checkout. All treatments include a free clinical consultation with UK-registered prescribers and discreet next-day delivery across the UK.

How the Mounjaro £20 discount Code UK Works at Cured Pharmacy

Applying your mounjaro discount code uk at Cured Pharmacy is straightforward. After completing your free online consultation and receiving prescriber approval, simply enter code WEIGHTLOSSNEW during checkout to receive £20 off your Mounjaro prescription. This discount applies to all tirzepatide doses, making genuine UK-licensed treatment more accessible without compromising on clinical safety or regulatory standards.

Unlike promotional offers that expire quickly or carry hidden terms, this discount is designed for new patients starting their weight loss journey. Your final price depends on the Mounjaro dose your UK prescriber determines is clinically appropriate based on your medical assessment, but the percentage saving remains consistent across all strengths.

Understanding Mounjaro Pricing in the UK Market

Why Mounjaro Costs Vary Between UK Pharmacies

Mounjaro pricing across UK online pharmacies reflects several factors including wholesale acquisition costs, clinical consultation fees, and pharmacy operational overheads. At Cured Pharmacy, transparent upfront pricing from £135.00 ensures you know the exact cost before completing your consultation, with no hidden fees or surprise charges at checkout.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) has structured our pricing model to remain competitive whilst maintaining full regulatory compliance with MHRA and GPhC standards. Every Mounjaro pen dispensed is genuine, UK-licensed medication stored and handled according to strict pharmaceutical protocols.

Clinical Evidence: Why Mounjaro Delivers Superior Weight Loss Results

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. This dual-action mechanism distinguishes it from single-pathway treatments by simultaneously activating glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, producing enhanced metabolic effects.

In the landmark SURMOUNT-1 trial, participants receiving the 15mg tirzepatide dose achieved an average body weight reduction of 20.9% over 72 weeks, compared to 3.1% in the placebo group [1]. The SURMOUNT-3 trial further demonstrated that patients maintained an average additional 5.5% weight loss when continuing tirzepatide after initial weight reduction, compared to those switched to placebo [2]. These results represent some of the most substantial weight loss outcomes observed in modern obesity pharmacotherapy.

Clinical trials also showed improvements in cardiometabolic markers including HbA1c, blood pressure, and lipid profiles across treatment groups [1]. However, individual results vary, and weight loss depends on adherence to the prescribed regimen alongside dietary modifications and increased physical activity as recommended by your prescriber.

Mounjaro vs Alternative Weight Loss Treatments Available in the UK

Comparing Injectable GLP-1 Receptor Agonists

Wegovy (semaglutide) and Saxenda (liraglutide) are alternative injectable treatments licensed in the UK for weight management. Wegovy, like Mounjaro, is administered once weekly, whilst Saxenda requires daily injections. In head-to-head trials, tirzepatide demonstrated superior weight loss compared to semaglutide, with the SURPASS-2 trial showing 12.4kg average weight reduction with tirzepatide 15mg versus 6.2kg with semaglutide 1mg over 40 weeks [3].

Your UK prescriber will assess which treatment aligns with your medical history, weight loss goals, and tolerance for injection frequency. Factors including existing health conditions, current medications, and previous treatment responses all influence this clinical decision. All three medications require ongoing prescriber monitoring and are subject to clinical assessment at each prescription renewal.

Oral Weight Loss Medications: Orlistat and Mysimba Options

For patients preferring oral medications, Cured Pharmacy offers several alternatives including Orlistat (available as generic, Xenical, Alli, and Orlos formulations) and Mysimba tablets. Orlistat works by inhibiting pancreatic lipase enzymes, reducing dietary fat absorption by approximately 25% [4]. This mechanism requires adherence to a reduced-calorie, lower-fat diet to minimise gastrointestinal side effects.

Mysimba combines naltrexone and bupropion to target neurological appetite regulation pathways. Clinical trials demonstrated an average 5-6% body weight reduction over 56 weeks compared to placebo when combined with lifestyle modifications [5]. Whilst oral medications typically produce more modest weight loss than injectable GLP-1 treatments, they suit patients with needle aversion or those seeking lower-cost entry points into medically supervised weight management.

Each medication class carries distinct side effect profiles, contraindications, and monitoring requirements. Your online consultation with a UK prescriber will determine which treatment offers the most appropriate risk-benefit balance for your individual circumstances.

How to Order Mounjaro with Your Discount Code at Cured Pharmacy

The Online Consultation and Prescription Process

Starting treatment requires completing a free online medical consultation through our GPhC-registered pharmacy platform. The assessment takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications to tirzepatide therapy. A UK-registered prescriber reviews your responses, typically within hours during business days.

If Mounjaro is deemed clinically appropriate, your prescriber will issue an electronic prescription specifying the starting dose (usually 2.5mg, titrating upwards as tolerated). You'll then proceed to checkout where code WEIGHTLOSSNEW applies your £20 discount automatically. We dispatch all orders in 100% discreet packaging via tracked courier, with most deliveries arriving next working day across mainland UK.

Prescription medications require ongoing clinical oversight. Your prescriber will schedule follow-up assessments to monitor weight loss progress, tolerability, and any dose adjustments needed. This ensures treatment remains safe and effective throughout your weight management journey whilst maintaining full compliance with MHRA prescribing guidelines.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
5. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss depends on adherence to prescribed treatment alongside lifestyle modifications.